Cerebroside synthesis as a measure of the rate of remyelination following cuprizone-induced demyelination in brain.
We studied markers of myelin content and of the rate of myelination in brains of mice between 8 and 20 weeks of age. During the 12-week time-course, control animals showed slight increases in the content of oligodendroglial-specific cerebroside, as well as cholesterol (enriched in, but not specific to, myelin). In contrast, synthesis of these lipids, as assayed by in vivo incorporation of (3)H(2)O, was substantial, indicating turnover of 0.4% and 0.7% of total brain cerebroside and cholesterol, respectively, each day. We also studied mice exposed to a diet containing 0.2% of the copper chelator, cuprizone. After 6 weeks 20%, and by 12 weeks, over 30% of brain cerebroside was gone. Demyelination was accompanied by down-regulation of mRNA expression for enzymes controlling myelin lipid synthesis (ceramide galactosyl transferase for cerebroside; hydroxymethylglutaryl-CoA reductase for cholesterol), and for myelin basic protein. Synthesis of myelin lipids was also greatly depressed. The 20% cerebroside deficit consequent to 6 weeks of cuprizone exposure was restored 6 weeks after return to a control diet. During remyelination, expression of myelin-related mRNA species, as well as cerebroside and cholesterol synthesis were restored to normal. However, in contrast to the steady state metabolic turnover in the control situation, all the cerebroside and cholesterol made were accumulated. To the extent that accumulating cerebroside is targeted for eventual inclusion in myelin (discussed) the rate of its synthesis is proportional to remyelination. With our assay, in vivo rates of cerebroside synthesis can be determined for a time window of the order of hours. This offers greater temporal resolution and accuracy relative to classical methods assaying accumulation of myelin components at time intervals of several days. We propose this experimental design, and the reproducible cuprizone model, as appropriate for studies of how to promote remyelination.
Jurevics
H
H
Neuroscience Center, Department of Microbiology, Program for Molecular Biology and Biotechnology, University of North Carolina, North Carolina, USA.
Hostettler
J
J
Muse
E D
ED
Sammond
D W
DW
Matsushima
G K
GK
Toews
A D
AD
Morell
P
P
D000818:Animals; D015415:Biomarkers; D001921:Brain / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D001933:Brain Stem / Q000187:drug effects / Q000378:metabolism; D002531:Cerebellum / Q000187:drug effects / Q000378:metabolism; D002554:Cerebrosides / Q000096:biosynthesis*; D002784:Cholesterol / Q000096:biosynthesis; D003471:Cuprizone / Q000494:pharmacology*; D005700:Galactosyltransferases / Q000235:genetics; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D006903:Hydroxymethylglutaryl CoA Reductases / Q000235:genetics; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D004676:Myelin Basic Protein / Q000378:metabolism*; D009186:Myelin Sheath / Q000187:drug effects* / Q000502:physiology; D051146:N-Acylsphingosine Galactosyltransferase; D013997:Time Factors; D014158:Transcription, Genetic / Q000187:drug effects
D015415:Biomarkers; D002554:Cerebrosides; D004676:Myelin Basic Protein; D003471:Cuprizone; D002784:Cholesterol; D006903:Hydroxymethylglutaryl CoA Reductases; D005700:Galactosyltransferases; D051146:N-Acylsphingosine Galactosyltransferase